Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Risk And Reward Seem Pretty Balanced At Seattle Genetics

Oncology biotech Seattle Genetics (NASDAQ:SGEN) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of antibody drug conjugate (or ADC) compounds, not to mention biotech enthusiasm in general, before getting caught up in the great biotech washout and fears tied to the safety of lead drug Adcetris and changes to clinical trials. Add in some concerns about competition from immuno-oncology drugs and there's a lot to digest. When it is all said and done, not all that much has changed on a "net basis" in my view - Seattle Genetics...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details